Top Stories
Top Stories
Pro Analysis

Health care still has potential, analysts say

Supporters of the Affordable Care Act celebrate as the opinion for health care is reported outside of the Supreme Court in Washington, D.C., on June 25, 2015.
Al Drago | CQ Roll Call | Getty Images

(The following article is a CNBC Pro free preview. Click here to subscribe).

Wall Street likes health care despite its vulnerability to political headwinds and underperformance this year.

The sector is down more than 2 percent this week after a new assault on drug pricing by Hillary Clinton and others, who criticized Mylan for dramatic price increases for its EpiPen allergy treatment.

The company's stock was slammed and biotech and drug stocks slumped. Mylan closed 0.7 percent lower Thursday, down nearly 12 percent for the week, while the iShares Nasdaq Biotechnology ETF (IBB) ended almost 1.2 percent lower on the day for a roughly 2.5 percent decline for the week.

The overall S&P 500 health care sector extended losses Thursday and was the second-worst performer in the index this year.